Correlation Between Mobileye Global and CRISPR Therapeutics

Can any of the company-specific risk be diversified away by investing in both Mobileye Global and CRISPR Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Mobileye Global and CRISPR Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Mobileye Global Class and CRISPR Therapeutics AG, you can compare the effects of market volatilities on Mobileye Global and CRISPR Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Mobileye Global with a short position of CRISPR Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Mobileye Global and CRISPR Therapeutics.

Diversification Opportunities for Mobileye Global and CRISPR Therapeutics

0.36

Correlation Coefficient

Mobileye Global  CRISPR Therapeutics

Weak diversification

The 3 months correlation between Mobileye and CRISPR is 0.36. Overlapping area represents the amount of risk that can be diversified away by holding Mobileye Global Class and CRISPR Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on CRISPR Therapeutics and Mobileye Global is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Mobileye Global Class are associated (or correlated) with CRISPR Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of CRISPR Therapeutics has no effect on the direction of Mobileye Global i.e., Mobileye Global and CRISPR Therapeutics go up and down completely randomly.

Pair Corralation between Mobileye Global and CRISPR Therapeutics

Given the investment horizon of 90 days Mobileye Global Class is expected to generate 1.48 times more return on investment than CRISPR Therapeutics. However, Mobileye Global is 1.48 times more volatile than CRISPR Therapeutics AG. It trades about 0.23 of its potential returns per unit of risk. CRISPR Therapeutics AG is currently generating about 0.02 per unit of risk. If you would invest  1,224  in Mobileye Global Class on October 8, 2024 and sell it today you would earn a total of  946.00  from holding Mobileye Global Class or generate 77.29% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	92.06%
Values	Daily Returns

Mobileye Global Class  vs.  CRISPR Therapeutics AG

Mobileye Global Class

Risk-Adjusted Performance

17 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Mobileye Global Class are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating essential indicators, Mobileye Global showed solid returns over the last few months and may actually be approaching a breakup point.

CRISPR Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in CRISPR Therapeutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, CRISPR Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Mobileye Global and CRISPR Therapeutics

The main advantage of trading using opposite Mobileye Global and CRISPR Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Mobileye Global position performs unexpectedly, CRISPR Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will offset losses from the drop in CRISPR Therapeutics' long position.

The idea behind Mobileye Global Class and CRISPR Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.